Medidata Solutions (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the sponsorship of its first clinical trial, which will evaluate the impact of mobile and cloud-based technology on patient engagement for improved health outcomes in the diabetes community.
By providing patients with the tools they need to track behavioral factors such as weight and physical activity, the pioneering study will test whether technology can increase the rates of therapy adoption and drive better outcomes for people with diabetes. Medidata’s study will use mHealth devices that provide immediate feedback to participants and are wirelessly linked to targeted messaging for unique patient engagement.
The study is in collaboration with Medidata Technology Partner Spaulding Clinical Research, a leading clinical research solution provider and medical device manufacturer, which will use its capabilities to enable the mHealth devices to connect to the Medidata Clinical Cloud™. Withings, a top innovator in health and wellness smart devices and applications, will supply the mHealth devices that will monitor the physical activity and weight of study participants. Leading endocrinologist Dr. Zachary T. Bloomgarden, Clinical Professor of Medicine, Endocrinology, Diabetes and Bone Disease at Mount Sinai Hospital in New York and co-editor of the Journal of Diabetes, is the study’s principal investigator. The initial feasibility stage of the study is slated to start in the fourth quarter of 2013 and will be followed by a randomized clinical trial.
“We are proud to sponsor our first clinical study in collaboration with Spaulding and Withings to see how disruptive technology can improve patient engagement and actually lead to better medical outcomes,” said Glen de Vries, president of Medidata Solutions. “Since our beginning, Medidata has pioneered the use of technology to transform clinical research, and the opportunity to see our technology used to improve patient health in the critical area of diabetes care is a logical—and incredibly exciting—extension.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts